Advanced search
Publication Cover
Melanoma Management Volume 2, 2015 - Issue 4
Submit an article Journal homepage
177
Views
0
CrossRef citations to date
0
Altmetric
Commentary

The end of the Beginning: PD-1 Inhibition as the New Standard of Care First-Line Immunotherapy in Metastatic Melanoma

Chad C Cherington1 Department of Medical Oncology,Mayo Clinic,13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
&
Alan H Bryce1 Department of Medical Oncology,Mayo Clinic,13400 East Shea Boulevard, Scottsdale, AZ 85259, USACorrespondence[email protected]
Pages 305-309 | Published online: 04 Dec 2015

References

  • Garbe C , EigentlerTK , KeilholzU , HauschildA , KirkwoodJM . Systematic review of medical treatment in melanoma: current status and future prospects . Oncologist16 ( 1 ), 5 – 24 ( 2011 ).
  • Robert C , ThomasL , BondarenkoIet al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma . N. Engl. J. Med.364 ( 26 ), 2517 – 2526 ( 2011 ).
  • Hodi FS , O’daySJ , McdermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma . N. Engl. J. Med.363 ( 8 ), 711 – 723 ( 2010 ).
  • Larkin J , Chiarion-SileniV , GonzalezRet al. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma . N. Engl. J. Med.373 , 1270 – 1271 ( 2015 ).
  • Postow MA , ChesneyJ , PavlickACet al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma . N. Engl. J. Med.372 ( 21 ), 2006 – 2017 ( 2015 ).
  • Robert C , LongGV , BradyBet al. Nivolumab in previously untreated melanoma without BRAF mutation . N. Engl. J. Med.372 ( 4 ), 320 – 330 ( 2015 ).
  • Daud A , RibasA , RobertCet al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001 . J. Clin. Oncol.33 , 15 ( 2015 ).
  • Robert C , SchachterJ , LongGVet al. Pembrolizumab versus ipilimumab in advanced melanoma . N. Engl. J. Med.372 ( 26 ), 2521 – 2532 ( 2015 ).
  • Wolchok JD , KlugerH , CallahanMKet al. Nivolumab plus ipilimumab in advanced melanoma . N. Engl. J. Med.369 ( 2 ), 122 – 133 ( 2013 ).
  • Weber JS , D’AngeloSP , MinorDet al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase III trial . Lancet Oncol.16 ( 4 ), 375 – 384 ( 2015 ).
  • Schadendorf D , HodiFS , RobertCet al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma . J. Clin. Oncol.33 ( 17 ), 1889 – 1894 ( 2015 ).
  • Topalian SL , SznolM , McdermottDFet al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab . J. Clin. Oncol.32 ( 10 ), 1020 – 1030 ( 2014 ).
  • Ribas A , PuzanovI , DummerRet al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase II trial . Lancet Oncol.16 ( 8 ), 908 – 918 ( 2015 ).
  • Ribas AS , LongJ. Get al. Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma . Presented at : Proceedings of the 106th Annual Meeting of the American Association for Cancer Research.Philadelphia, PA, USA , 18–22 April 2015 ( Abstract CT101 ).
  • Weber JK et al. A Phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA4 therapy . Presented at : ESMO Annual Meeting.Madrid, Spain , 26–30 September 2014 ( Abstract LBA3 ).
  • Sznol M , KlugerHM , CallahanMKet al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO 4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract LBA9003 ( 2014 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.